|Cancer Stem Cell News 5.28 July 20, 2016|
Investigators introduced a novel micro/nanotechnology-based chip platform for performing live-cell interrogation of patient-derived glioma stem cell cultures with single-clone resolution. [Nano Lett]
The authors report a role for KANSL2 in regulation of stemness in glioblastoma, which is characterized by heterogeneous tumor stem-like cells associated with therapy resistance and disease relapse. [Cancer Res]
Scientists previously reported the oncogenic role of paired-like homeodomain 2 (PITX2) in esophageal squamous cell carcinoma (ESCC). In this study, they aimed to identify the microRNA regulators of PITX2 and the mechanism underlying the pathogensis of ESCC. [Clin Cancer Res]
Scientists characterized the role of DICER in glioblastoma (GB), specifically demonstrating its effects on the ability of glioma stem-like cells to form tumors in a mouse model of GB. [Oncotarget]
Researchers analyzed the plasticity of lung cancer cells and found that lung non-cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can dedifferentiate into CSCs/CICs in accordance with the expression of stem cell transcription factor SOX2. [Oncotarget]
Scientists evaluated the effect of chronic alcohol exposure on mammary tumor development/metastasis in MMTV-neu transgenic mice and investigated the cell signaling in response to alcohol exposure in breast cancer cells overexpressing ErbB2/HER2. [Mol Cancer]
Resveratrol’s effects on cell proliferation, sphere-forming ability, and invasion were tested using multiple patient-derived glioblastoma multiforme stem-like cell lines and established U87 glioma cells, and changes in oncogenic AKT and tumor suppressive p53 were analyzed. [J Neurosurg]
Experiments using a large amount of cancer stem-like cells/cancer-initiating cells are technically very difficult. Researchers isolated single cell clones from side population cells and main population cells derived from the human colon cancer cell line SW480. [PLoS One]
Scientists analyzed the expression of putative cancer stem cell (CSC) markers-CD24, CD44, epithelial cell adhesion molecule, CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 pancreatic adenocarcinoma-derived cell lines and by immunohistochemistry in three corresponding tumor samples. [PLoS One]
The authors review the processes of neural crest development and tumorigenesis and they discuss the previously identified markers for cancer stem cell subpopulations identified in neural crest tumors and their role in neural crest tumor biology. [J Cell Biochem]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Vigilant Biosciences, Inc. announced a presentation of data related to proof-of-concept studies by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, titled CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients. [Press release from Vigilant Biosciences, Inc. discussing research presented at American Head and Neck Society 9th International Conference on Head and Neck Cancer, Seattle]
| From our sponsor: |
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols. Watch the video.
Guardant Health announced a strategic collaboration with OncoMed Pharmaceuticals. Using Guardant Health’s digital sequencing technology, the companies have developed a custom blood test that looks for specific biomarkers relevant to OncoMed’s ongoing Phase Ia/Ib trial of its anti-RSP03 antibody. [ScienceInsider]
Eiger BioPharmaceuticals, Inc. announced the completion of dosing of LOWR HDV-3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 3) at the NIH Clinical Center in Bethesda, Maryland. [Eiger BioPharmaceuticals, Inc.]
Cerulean Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer. [Cerulean Pharma Inc.]
The United States Patent and Trademark Office (USPTO) has granted Cantargia AB’s patent application concerning IL1RAP as a target molecule for antibody therapy of several solid tumor types. The granted patent follows the Notice of Allowance that was issued and communicated in June 2016. [Cerulean Pharma Inc.]
The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. [National Institutes of Health]
Britain’s hopes of leading the world in revolutionary therapies that regenerate damaged body parts are under threat because the NHS drugs watchdog cannot properly evaluate them, a report says. [The Guardian]
Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News]
The political and economic crisis in Venezuela continues to worsen. As the price of oil — the country’s major export — has fallen, Venezuela has struggled to pay for imported goods while maintaining socialist economic policies put in place by former president Hugo Chávez. [Nature News]
As the International AIDS Conference kicked off in Durban, South Africa, two of the nation’s most prominent biomedical research institutions announced that they will marry and combine resources to attack the raging coepidemic of tuberculosis and HIV in the region. [ScienceInsider]
For researchers worried about the future of science in the United Kingdom, the news was something to hold onto. Late on Friday, Jo Johnson announced he will remain as science minister, despite a massive shakeup of the government cabinet. [ScienceInsider]
More than a thousand Turkish university staff have been ordered to resign their faculty leadership positions — and others expect to be sacked — in the aftermath of the country’s failed coup. As president Recep Tayyip Erdoğan continues to clamp down on political opposition, the Turkish Council of Higher Education has called for all 1,577 of the country’s university deans — the staff that head up each institution’s various academic faculties — to leave their posts. [Nature News]
The Netherlands has launched what researchers say is the world’s first national fund dedicated to replication studies: a pot of €3 million (US$3.3 million) over the next 3 years for Dutch scientists to test whether they can reproduce important research results in social and medical sciences. [Nature News]
NEW 28th European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium
Visit our events page to see a complete list of events in the cancer stem cell community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.28 | Jul 20 2016